In that trial , progression-free survival was significantly improved in the pazopanib arm ( median , 4.6 vs 1.6 months ; hazard ratio , 0.31 ; P < .001 ) , and toxicity of pazopanib consisted mainly of fatigue , diarrhea , nausea , weight loss , and hypertension .